Key facts
- Vetigenics’s last known valuation is $26.0M (Feb 2025).
- It has raised $7.3M; the latest was Seed Round ($6.0M) in Feb 2025.
- Notable investors include Wilson Sonsini Goodrich & Rosati, Astralabs, National Cancer Institute, Penn Center for Innovation, University of Pennsylvania — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Vetigenics
- ·The full record, as it builds
Funding rounds
No funding rounds for Vetigenics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vetigenics
Operator of an animal health biotechnology company intended to improve the lives of companion animals through science and medicine. The company offers a proprietary, species-specific, phage display technology that creates safe, effective therapeutics to treat cancer, autoimmune, inflammatory, and infectious diseases, enabling veterinarians to improve the treatment options to offer pet parents for their beloved family members.
- Sector
- Business Products and Services (B2B)
- HQ
- Philadelphia, PA, United States
- Founded
- 2017
- Employees
- 10
- Website
- vetigenics.com/
- Ownership
- Privately Held (backing)
Vetigenics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vetigenics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vetigenics in its N-PORT filings yet. We sweep new filings monthly.